Literature DB >> 9760987

Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types.

S Sorrentino1.   

Abstract

Human extracellular ribonucleases (RNase), together with other members of the mammalian RNase A superfamily, can be classified into four different RNase families on the basis of their structural, catalytic and/or biological properties. Their occurrence and main distinctive features have been described, and the information available on their catalytic properties has been analysed and discussed in comparison with those of other animal RNases. On the basis of some results obtained with various single- and double-stranded polyribonucleotides, it has been proposed that while pancreatic-type (pt) RNases could be defined as single-strand/pyrimidine 'preferring' ribonucleases, mammalian nonpancreatic-type (npt) RNases may be referred to as single-strand/pyrimidine 'specific' ribonucleases. In addition, some data concerning human nptRNases may support the suggestion [Cuchillo et al. (1993) FEBS Lett. 333: 207-210] that the enzyme 'ribonuclease' should be reclassified as 'transferase'.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760987     DOI: 10.1007/s000180050207

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  36 in total

1.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

Review 2.  The 2',3'-cAMP-adenosine pathway.

Authors:  Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

3.  Structural basis of RNA binding by leucine zipper GCN4.

Authors:  Yaroslav Nikolaev; Konstantin Pervushin
Journal:  Protein Sci       Date:  2012-03-29       Impact factor: 6.725

4.  2',3'-cAMP, 3'-AMP, and 2'-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors.

Authors:  Edwin K Jackson; Jin Ren; Delbert G Gillespie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-27       Impact factor: 4.733

Review 5.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 6.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

7.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

Review 8.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Oligomerization of bovine ribonuclease A: structural and functional features of its multimers.

Authors:  Massimo Libonati; Giovanni Gotte
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

10.  Zebrafish RNase T2 genes and the evolution of secretory ribonucleases in animals.

Authors:  Melissa S Hillwig; Ludmila Rizhsky; Ying Wang; Alisa Umanskaya; Jeffrey J Essner; Gustavo C MacIntosh
Journal:  BMC Evol Biol       Date:  2009-07-20       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.